What is the appropriate management for an infusion reaction to amivantamab?

Management of Amivantamab Infusion Reactions

For amivantamab infusion reactions, immediately stop the infusion, maintain IV access, assess vital signs and ABCs, and manage based on severity: Grade 1-2 reactions require slowing or temporarily stopping the infusion with symptomatic treatment (antihistamines and corticosteroids), then resuming at 50% rate; Grade 3-4 reactions require permanent infusion cessation with aggressive treatment including epinephrine for anaphylaxis. 1, 2

Immediate Actions When Reaction Occurs

Stop the infusion immediately and maintain IV access 1. Assess the patient's airway, breathing, circulation (ABCs) and level of consciousness 1.

Patient Positioning

• Hypotension: Place in Trendelenburg position
• Respiratory distress: Sit patient upright
• Unconscious: Recovery position 1

Administer oxygen if needed and call for medical assistance immediately 1.

Severity-Based Management Algorithm

Grade 1-2 Reactions (Mild to Moderate)

These represent 90% of amivantamab infusion reactions and typically present with chills, dyspnea, flushing, nausea, chest discomfort, or vomiting 2, 3.

Management approach:

• Stop or slow the infusion rate 1
• Administer symptomatic treatment:
  • H1/H2 antihistamines: Diphenhydramine 25-50 mg IV plus ranitidine 50 mg IV 1
  • Corticosteroids: Methylprednisolone 1-2 mg/kg IV every 6 hours 1
  • Antipyretics as needed 1
• Once stable, restart infusion at 50% of the original rate and titrate to tolerance 1, 2

Critical timing detail: Most amivantamab IRRs (98%) occur on Cycle 1 Day 1 or Day 2, with median onset at 60 minutes into infusion 2, 3. The median time to resolution is also 60 minutes 3.

Grade 3 Reactions (Severe)

Management approach:

• Stop the infusion completely 1
• Aggressive symptomatic treatment with antihistamines and corticosteroids as above 1
• If symptoms improve to Grade 2, treatment can be resumed at half the rate and titrated to tolerance 1
• If Grade 3 reaction recurs at subsequent infusion, permanently discontinue 1

Grade 4 Reactions or Anaphylaxis

When patient meets anaphylaxis criteria, this is life-threatening and requires immediate intervention:

• Epinephrine 0.01 mg/kg (maximum 0.5 mL of 1 mg/mL) intramuscularly into lateral thigh, repeat every 5-15 minutes as needed 1
• Fluid resuscitation: 1-2 liters normal saline at 5-10 mL/kg in first 5 minutes, then crystalloids/colloids in 20 mL/kg boluses 1
• Combined H1/H2 antihistamines: Diphenhydramine 25-50 mg IV plus ranitidine 50 mg IV 1
• Corticosteroids: Methylprednisolone 1-2 mg/kg IV every 6 hours (prevents biphasic reactions) 1

For refractory hypotension despite epinephrine:

• Dopamine 2-20 mcg/kg/min titrated to blood pressure 1
• Vasopressin 0.01-0.04 U/min or norepinephrine for epinephrine-unresponsive cases 1

For bradycardia (rare but reported with amivantamab 4):

• Atropine 600 mcg IV 1
• If patient on beta-blockers: Glucagon 1-5 mg IV over 5 minutes 1

Permanently discontinue amivantamab for Grade 4 reactions 1, 2

Post-Reaction Monitoring

• Monitor vital signs continuously until complete resolution 1
• Observe for 24 hours after severe reactions to detect biphasic reactions 1
• Document the reaction severity, timing, symptoms, and interventions used 1

Amivantamab-Specific Context

Infusion reactions occur in 67% of patients receiving amivantamab, but only 2% are Grade 3-4 2. The split-dose strategy (350 mg on Day 1, remainder on Day 2 for first cycle) significantly reduces IRR severity 2, 3.

Importantly, first-infusion IRRs do not compromise subsequent infusions - 85% of patients who had aborted Day 1 infusions successfully completed Day 2 infusions 2. Only 1% of patients discontinued amivantamab due to IRR 2.

Rechallenge Considerations

Do not attempt rechallenge for Grade 3 or higher reactions or true anaphylaxis 1. For Grade 1-2 reactions, rechallenge with reduced infusion rate and additional premedication (corticosteroids and antihistamines) is usually successful 1.

Common Pitfalls to Avoid

• Do not confuse cytokine release syndrome with anaphylaxis - CRS can be managed with short-term infusion cessation and symptomatic treatment, then restarted at half rate 1
• Do not delay epinephrine in true anaphylaxis - it must be given immediately, not after antihistamines fail 1
• Do not use corticosteroids as first-line for anaphylaxis - they prevent biphasic reactions but are not critical for acute management 1
• Monitor for atypical presentations including acute pain flare in patients with pre-existing cancer pain 5 or isolated bradycardia 4